FY2025 · ended May 25, 2025 · Revenue $128.87M, +0.5% YoY · Filed Mar 16, 2026
Lifecore Biomedical, Inc. (LFCR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended May 25, 2025, it reported revenue of $128.9 million and a net loss of $38.7 million. Free cash flow was -$13.6 million. As of Sep 30, 2026 it held $23.0 million in cash and investments and $167.9 million in total debt.
Revenue (TTM)
$119.13M
-8.6% vs year-ago TTM
Net income (TTM)
$-62.37M
-39.7% vs year-ago TTM
Operating cash flow (TTM)
$14.80M
+368.0% vs year-ago TTM
Free cash flow (TTM)
$10.16M
EPS (TTM)
$-1.76
-37.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
37.48M
+0.2% vs prior year
Net cash
$-144.88M
as of Sep 30, 2026
Operating margin
2.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFCR (Nasdaq)
- Fiscal year ends
- May 25
- Incorporated in
- DE
- Headquarters
- Chaska, MN
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1005286
- Former names
- LANDEC CORP \CA\ (until Nov 7, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 May 25, 2025 |
FY 2024 May 26, 2024 |
FY 2023 May 28, 2023 |
FY 2022 May 29, 2022 |
FY 2021 May 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $128.9M | $128.3M | $103.3M | $111.3M | $100.9M |
| Operating income | -$17.2M | -$8.8M | -$21.8M | -$11.8M | -$8.8M |
| Net income | -$38.7M | $12.0M | -$99.6M | -$116.7M | -$32.3M |
| Diluted EPS | -$1.27 | $0.33 | -$3.32 | -$3.97 | -$1.10 |
| Operating cash flow | -$206,000 | $257,000 | -$17.4M | -$22.6M | $16.5M |
| Free cash flow | -$13.6M | — | — | -$48.8M | -$2.8M |
| Total assets | $239.3M | $254.0M | $253.5M | $274.7M | $501.9M |
| Total liabilities | $191.9M | $200.1M | $218.5M | $186.9M | $299.9M |
| Stockholders' equity | $1.3M | $11.3M | -$4.2M | $87.8M | $201.9M |
| Cash and investments | $8.3M | $8.5M | $19.1M | $991,000 | $763,000 |
| Total debt | $138.1M | $133.7M | $95.8M | $113.2M | $192.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 28, 2026 | Sep 27, 2026 |
All 1005 Lifecore Biomedical, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.